NeuroMetrix (NASDAQ: NURO) was flying in the market Tuesday morning, and for good reason. The company received Breakthrough Device Designation from the FDA for its Quell device. Here’s what’s going on:
NURO Stock Climbs on Breakthrough Device Designation
In the press release, NeuroMetrix said the Breakthrough Designation surrounds the use of Quell as a means to reduce moderate to severe symptoms of chemotherapy induced peripheral neuropathy that have persisted for at least 6-months following the end of chemotherapy…
The post NeuroMetrix (NURO) Stock Rockets on FDA Breakthrough Device Designation originally appeared at CNA Finance.